DIABETOLOGIA:皮肤自身荧光可以预测2型糖尿病、心血管疾病和普通人群的死亡率?

2019-04-06 不详 网络

早期的研究表明,用年龄阅读器测量的皮肤自身荧光可估计皮肤年龄的累积,其随着年龄的增长而增加,并与代谢综合征和2型糖尿病有关。在本研究中,我们检验了皮肤自身荧光的测量是否可以预测普通人群4年内发生2型糖尿病、心血管疾病(CVD)和死亡的风险。

早期的研究表明,用年龄阅读器测量的皮肤自身荧光可估计皮肤年龄的累积,其随着年龄的增长而增加,并与代谢综合征2糖尿病有关。在本研究中,我们检验了皮肤自身荧光的测量是否可以预测普通人群4年内发生2糖尿病血管疾病(CVD)和死亡的风险。

在这项前瞻性分析中,我们纳入了72,880名荷兰生命线队列研究的参与者,他们在2007年至2013年间接受了基线调查,已经验证了可用的基线皮肤自身荧光值,并且不知道患有糖尿病CVD。随访时,个体通过自我报告或空腹血糖≥7.0 mmol/l或糖化血红蛋白≥48 mmol/mol(6.5%)诊断为突发2型糖尿病。参与者通过自我报告被诊断为突发CVD(心肌梗死、冠状动脉介入、脑血管意外、短暂性缺血发作、间歇性跛行或血管手术)。使用城市个人记录数据库确定死亡率。

结果显示,在中位随访4年后(范围0.5-10)1056名参与者(1.4%)发展为2型糖尿病,1258(1.7%)诊断为CVD, 928(1.3%)死亡。2型糖尿病和/CVD患者以及已经死亡的患者(p < 0.001)的皮肤自发荧光基线升高,而存活下来且没有出现这两种疾病的患者的皮肤自发荧光基线升高。皮肤自身荧光可以预测2型糖尿病、CVD和死亡率的发生,不受代谢综合征、葡萄糖和糖化血红蛋白等传统危险因素的影响。

研究表明,非侵入性皮肤自身荧光检测,不依赖于血糖测量和代谢综合征,对筛查未来2型糖尿病、CVD和死亡率的风险具有临床价值。

原始出处:

Robert P. van WaateringeSkin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1761083, encodeId=1ab31e61083eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 18 22:41:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707790, encodeId=44a71e0779057, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Fri Jan 24 14:41:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639073, encodeId=1c1616390e3d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 27 15:41:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498553, encodeId=1ba61498553bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614771, encodeId=524b1614e71b8, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042365, encodeId=836a104236512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 01:41:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1761083, encodeId=1ab31e61083eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 18 22:41:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707790, encodeId=44a71e0779057, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Fri Jan 24 14:41:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639073, encodeId=1c1616390e3d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 27 15:41:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498553, encodeId=1ba61498553bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614771, encodeId=524b1614e71b8, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042365, encodeId=836a104236512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 01:41:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1761083, encodeId=1ab31e61083eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 18 22:41:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707790, encodeId=44a71e0779057, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Fri Jan 24 14:41:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639073, encodeId=1c1616390e3d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 27 15:41:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498553, encodeId=1ba61498553bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614771, encodeId=524b1614e71b8, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042365, encodeId=836a104236512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 01:41:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1761083, encodeId=1ab31e61083eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 18 22:41:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707790, encodeId=44a71e0779057, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Fri Jan 24 14:41:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639073, encodeId=1c1616390e3d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 27 15:41:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498553, encodeId=1ba61498553bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614771, encodeId=524b1614e71b8, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042365, encodeId=836a104236512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 01:41:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1761083, encodeId=1ab31e61083eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 18 22:41:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707790, encodeId=44a71e0779057, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Fri Jan 24 14:41:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639073, encodeId=1c1616390e3d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 27 15:41:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498553, encodeId=1ba61498553bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614771, encodeId=524b1614e71b8, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042365, encodeId=836a104236512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 01:41:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1761083, encodeId=1ab31e61083eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Nov 18 22:41:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707790, encodeId=44a71e0779057, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Fri Jan 24 14:41:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639073, encodeId=1c1616390e3d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Aug 27 15:41:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498553, encodeId=1ba61498553bf, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614771, encodeId=524b1614e71b8, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Mon Apr 08 13:41:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042365, encodeId=836a104236512, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 07 01:41:00 CST 2019, time=2019-04-07, status=1, ipAttribution=)]
    2019-04-07 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Lancet:适度饮酒并不能降低心血管疾病风险!

squamous一直以来,很多研究表明适度摄入酒精,相比禁酒和大量饮酒,与心血管风险降低相关。东亚的研究可帮助明确这种相关性是否存在因果关系,因为两个常见的遗传突变可明显影响酒精的摄入模式。研究人员通过这两个突变评估心血管风险与基因型预测的平均酒精摄入在男性中的相关性,并与在女性中的发现进行对比。2004年6月25日-2008年7月15日,研究人员从中国的10个地区招募了512715位成年人,记录

Eur Heart J:心血管疾病妇女的妊娠结局

由此可见,心脏病女性的孕产妇死亡率或心力衰竭率很高。然而,从2010年开始,尽管包含更多高风险妊娠,但这些发生率仍然下降。PAH女性的并发症发生率最高。

Circulation:复杂性较低的先心病成人患者心血管疾病的发病率高

与一般人群相比,低复杂性ACHD个体的不良心血管事件负担较重,而这不能由传统心血管危险因素来解释。

2019 ACC/AHA指南:心血管疾病的一级预防

2019年3月17日,《2019 ACC/AHA心血管疾病一级预防指南》在第68届美国心脏病学会科学年会(ACC 2019)上正式发布。

JCEM:维生素D和动脉粥样硬化心血管疾病

由此可见,目前维生素D补充剂的随机试验不支持心血管健康,但证据尚无定论。需要进行额外的随机试验,以评估更大数量的低维生素D患者,更长的随访时间,以及更高的维生素D剂量,以指导临床实践。

J Exp Med:揭示促甲状腺激素加重血管炎症和动脉粥样硬化形成新机制

甲状腺功能减退症(hypothyroidism,简称甲减),是多种原因引起的甲状腺激素(TH)合成、分泌或生物效应不足所致的一组内分泌疾病,仅有血清促甲状腺激素(TSH)水平轻度升高,而血清甲状腺激素(FT4,FT3)水平正常,患者无甲减症状或仅有轻微甲减症状,称为亚临床甲状腺功能减退症(subclinical hypothyroidism,简称亚临床甲减),又称为轻微型甲减,潜伏期型甲减、生化性